Introduction
Bacterial meningitis is a potentially catastrophic infectious disease associated with substantial mortality and a risk of permanent disability in survivors. 1 Despite ongoing advances in diagnostic methods and treatment strategies, mortality remains as high as 30% in pneumococcal meningitis and 5-10% in meningococcal meningitis. 2, 3 However, outcomes are improved by prompt therapy. [4] [5] [6] It is critical that clinicians recognise the need to prioritise initial investigations while not delaying life-saving treatment with dexamethasone and antibiotics, which should be administered as soon as possible within the first hour following presumptive diagnosis. This article will focus on diagnostic and management issues that a clinician will face when dealing with a suspected case of community-acquired bacterial meningitis in an adult. While we do not address non-infectious causes of meningitis, such as those caused by malignancy, medications or autoimmune conditions, these should also be considered in the differential diagnosis of meningitis.
Diagnosis Clinical features and clues to the responsible pathogen
A patient who presents with recent onset of headache, fever, neck stiffness or altered mental state would prompt most clinicians to consider the possibility of meningitis. At least two of these four features will be present in 95% of patients with bacterial meningitis and should lead to urgent diagnostic work-up for this condition. 7 The classic triad of bacterial meningitis consists of fever, neck stiffness and altered mental state; however, reliance on all three of these signs being present will result in more than 50% of cases of bacterial meningitis being missed. 7 Some clinical features and patient characteristics may provide clues to the responsible pathogen. Meningitis due to Neisseria meningitidis may begin with an influenzalike illness, with symptoms such as fever, muscle aches and vomiting, before meningitis becomes clinically apparent. Rapid onset and progression of symptoms over hours is typical and can be helpful to distinguish this condition from self-limiting viral infections. A patient with meningitis and a non-blanching petechial or purpuric rash strongly suggests meningococcal disease, although the rash may also be blanching, maculopapular or absent. The level of suspicion must be particularly high for patients presenting in the context of an established meningococcal epidemic. 8 Meningitis due to Streptococcus pneumoniae should be suspected in patients with predisposing conditions, such as otitis media, sinusitis, mastoiditis, cerebrospinal fluid (CSF) leak, cochlear implants, asplenia, human immunodeficiency virus (HIV) infection or other immunosuppressive conditions or medications. 9 Patients at risk of Listeria monocytogenes meningitis include those aged ≥50, those taking longterm glucocorticoids or other immunosuppressive drugs and those with diabetes, alcoholism, cirrhosis, end-stage renal failure, malignancy, HIV infection or organ transplantation. 10 Neuroimaging: computed tomography before lumbar puncture is not usually required In many patients with meningitis, performing a lumbar puncture (LP) and starting empirical treatment are unnecessarily delayed while waiting for computed tomography (CT) of the head. 11 CT prior to LP should not be performed for most patients for several reasons. First, and most importantly, if a patient is not pretreated with antibiotics, the sequence of CT followed by LP followed by antibiotics causes an unacceptable delay in starting treatment and increases the likelihood of an unfavourable outcome. 6 Second, the yield of CT is low in patients who do not have clinical features of raised intracranial pressure (ICP), with 97% having a normal result. 12 Third, if a patient is pretreated with antibiotics prior to CT and LP, the yield of CSF culture will be significantly decreased, although a diagnosis can often still be obtained through polymerase chain reaction (PCR) testing.
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CT prior to LP is recommended for patients who have one or more clinical features that increase the probability of having raised ICP, to attempt to identify those most at risk of brain herniation following LP. However, guidelines differ as to which clinical features constitute an indication to perform CT prior to LP ( Table 1 ). The lack of consensus about which patients should undergo a CT prior to LP reflects uncertainties about the reliability of CT scans to detect raised ICP 16 and about whether CT evidence of raised ICP is associated with an increased risk of brain herniation following LP. 4 Scepticism of the value of neuroimaging is reflected in the Swedish guideline, 15 which recommends CT prior to LP only for patients who have signs of imminent brain herniation, focal neurological deficits (not including cranial nerve palsies) or who have had cerebral symptoms for more than 4 days (which increases the likelihood of cerebral pathology other than acute meningitis). A recent study suggested that use of the Swedish guideline in place of the Infectious Diseases Society of America guideline might result in a shorter time to initiation of therapy, an approximately 33% reduction in mortality and an approximately 24% increase in favourable outcome in patients with bacterial meningitis. 17 This suggests that more stringent selection of patients who undergo CT before LP has the potential to significantly improve outcomes in patients with bacterial meningitis. If CT before LP is deemed to be necessary, it is vital that blood cultures are taken, and dexamethasone and antibiotics are started without delay.
CSF analysis
CSF analysis is of vital importance in suspected meningitis as clinical characteristics alone are unable to distinguish meningitis from other diagnoses, and bacterial from nonbacterial aetiologies. 18 For the majority of patients who do not require CT prior to LP and do not have another clinical contraindication to LP, CSF analysis should be performed within 1 h of the presumptive diagnosis of meningitis without awaiting further investigations, such as platelet count or coagulation studies. Clinical contraindications to LP include anticoagulation, clinical evidence of disseminated intravascular coagulation and local infection or loss of skin integrity at the puncture site. 19 LP is safe in patients taking aspirin, but safety is less well established for those taking other anti-platelet agents, such as clopidogrel or ticagrelor, or for those on dual antiplatelet therapy; deferring LP is recommended in these circumstances. 19 Appearance and opening pressure Appearance of the CSF should be noted; cloudy or turbid fluid suggests a significant concentration of leukocytes in the sample (although xanthochromia, elevated protein concentration or a high number of bacterial colonyforming units may also cause this appearance). 13 A manometer should be used to measure opening pressure in the lateral decubitus position; in bacterial meningitis, opening pressure is typically >20 cm H 2 O, although other factors, such as patient anxiety and positioning, may artifactually elevate this. 13 
Gram stain
Once CSF is delivered to the laboratory, a Gram stain should be rapidly performed. If bacteria are seen, this provides a presumptive microbiological diagnosis upon which directed therapy can be based. 13 The presence of Gram-positive cocci suggests S. pneumoniae, Gramnegative diplococci N. meningitidis and Gram-positive bacilli L. monocytogenes (which are the first, second and third most common causes of community-acquired bacterial meningitis in adults, respectively). 10 Gramnegative bacillary meningitis is rare in immunecompetent adults unless indwelling neurosurgical devices are present. 1 The likelihood of a positive Gram stain ranges from 25% to 97% and is highly correlated with the concentration of bacterial colony-forming units in the CSF; a negative stain therefore cannot exclude this diagnosis. 13 A positive Gram stain is more likely in pneumococcal meningitis compared with meningococcal or Listeria meningitis and is less likely if antibiotics have been given prior to LP. 20 
Cell counts and chemistry
If the Gram stain is negative, the CSF leukocyte count is often helpful in distinguishing bacterial from nonbacterial meningitis (Table 2) . Meningitis is confirmed when the leukocyte count in the CSF exceeds 5 cells/μL. A leukocyte count of ≥1000 cells/μL with a neutrophilic predominance is highly suggestive of bacterial meningitis, 1 whereas <1000 cells/μL with a lymphocytic predominance is more consistent with viral meningitis, tuberculous meningitis (TBM) or cryptococcal meningitis. 20 Bacterial meningitis due to L. monocytogenes is an important exception, with approximately 60% of cases having a leukocyte count of <1000 cells/μL, which may be lymphocytic. 10 If a traumatic tap occurs, the leukocyte count should be corrected by deducting one leukocyte for every 500-1000 red cells in the CSF. 23 It is critical that these leukocyte ranges are not viewed as absolute cut-off values. Bacterial meningitis can present with counts significantly lower than 1000 cells/μL, and rare cases with normal counts on initial CSF analysis have been described. 24 In addition, 10% of cases have a lymphocytic predominance. 13 In very early presentations of viral meningitis, there may be a neutrophilic predominance, which typically becomes lymphocytic within 48 h.
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CSF protein is usually elevated in meningitis of both bacterial and viral aetiology due to increased permeability of the blood-brain barrier as a consequence of inflammation. 1 This elevation is typically greater in bacterial and TBM (≥1 g/L) than in viral meningitis (<1 g/L), with the exception of meningitis due to the herpes simplex virus (HSV) or varicella zoster virus (VZV), where protein may be ≥1 g/L. 20, 26 As with the leukocyte count, CSF protein should be corrected for a traumatic tap by deducting 0.01 g/L for every 1000 red cells. 23 Hypoglycorrhachia (low CSF glucose) is another helpful pointer towards bacterial meningitis, although it is also seen in TBM and cryptococcal meningitis. 21, 27 CSF glucose varies proportionally to blood glucose, with a normal CSF-to-blood glucose ratio being 0.6. 28 A normal ratio is usually found in viral meningitis. 20 A ratio of ≤0.5 has 100% sensitivity for bacterial meningitis but specificity of only 57%. 22 When a ratio of ≤0.23 is used, specificity improves to 99% but at the cost of sensitivity. 29 These values are minimally affected by pretreatment with antibiotics. The CSF-to-blood glucose ratio may be less helpful in hyperglycaemic patients as CSF glucose levels begin to plateau once blood glucose exceeds 5.5 mmol/L (100 mg/dL). 28 Given that no single CSF parameter can reliably distinguish bacterial from non-bacterial causes of meningitis, clinicians must exercise caution when interpreting these parameters. Consideration of clinical features and CSF parameters together often cannot confidently exclude the possibility that a patient has bacterial meningitis. In these cases, most experienced clinicians would err on the side of caution and treat for bacterial meningitis while awaiting further microbiological results. 30 
Culture
The sensitivity of culture is 60-90% for CSF collected before antibiotic treatment has been started, with positive results generally available within 24-48 h. 13 The yield of culture decreases significantly in the pretreated patient, in whom other tests, such as PCR or bacterial antigen testing (BAT), may be necessary to identify the pathogen. In addition to CSF cultures, blood cultures should be taken in all cases of suspected bacterial meningitis as a pathogen may be isolated through this route despite negative Gram stain and culture of CSF. 14 
Bacterial antigen testing
Many laboratories offer BAT on CSF samples, most often for the detection of S. pneumoniae. The pneumococcal BAT has been reported to have a specificity in excess of 95% for pneumococcal meningitis and a sensitivity ranging between 67% and 100%. 13 This test can be performed within minutes of the sample arriving in the laboratory and can provide more rapid confirmation of pneumococcal meningitis than either PCR or culture. However, given the variable sensitivity of this test, a negative pneumococcal BAT should not justify the early discontinuation of S. pneumoniae-specific therapy, such as dexamethasone or vancomycin, if this has been commenced. In Australia, a positive pneumococcal BAT is considered an indication for adding vancomycin to the empirical antibiotic regimen. 31 
Polymerase chain reaction
Multiplex PCR assays can detect the presence of many important bacterial and viral pathogens in CSF, including N. meningitidis, S. pneumoniae, enteroviruses, HSV, VZV and mumps virus, with sensitivity and specificity ≥90%. 13 Misleading positive viral results have occasionally been described in cases of confirmed bacterial meningitis. 32 PCR has been used successfully for the 33 In Australia and New Zealand, the accessibility of multiplex PCR varies based on location; a result can be available within hours if the assay is available in-house but may take days if the sample needs to be delivered to a reference laboratory. When compared with bacterial culture, PCR is much less affected by pretreatment with antibiotics, with one study showing sensitivity of 89% in samples collected on days 1-3 of antibiotic treatment, 70% on days 4-6 and 33% on days 7-10. In comparison, no CSF cultures were positive in samples collected more than 1 day after initiation of antibiotics. 34 Lactate, procalcitonin and C-reactive protein CSF lactate, serum procalcitonin (PCT) and serum Creactive protein (CRP) may be helpful in distinguishing bacterial from non-bacterial meningitis. A meta-analysis reported that a CSF lactate of ≥35 mg/dL (3.9 mmol/L) had 93% sensitivity and 99% specificity for bacterial meningitis. 35 CSF lactate is not proportional to serum lactate, but it may be elevated in central nervous system (CNS) conditions other than bacterial meningitis, such as viral encephalitis or seizures.
14 Another meta-analysis showed that elevated serum PCT had 90% sensitivity and 98% specificity for bacterial meningitis and was more sensitive and specific than CRP; the definition of elevated PCT varied between the individual studies, with cut-off values from ≥0.25 to ≥2.13 ng/mL (normal <0.1 ng/mL). 36 PCT is particularly helpful in the diagnosis of early bacterial meningitis as it becomes detectable within 3-4 h of onset of symptoms, compared with the 12-24 h that CRP takes to rise. 37 When PCT measurement is not readily available, CRP may provide some useful information; one study showed that patients with bacterial meningitis had a median CRP of 162 mg/L (95% confidence interval 39-275) compared with a median of 13 mg/L (95% confidence interval 9-17) in non-bacterial meningitis. 38 Pretreatment with antibiotics decreases the sensitivity of all three of these tests. 35, 36, 38 Aseptic meningitis: not synonymous with viral meningitis Viral meningitis is most commonly caused by the enteroviruses and is self-limiting, although HSV or VZV meningitis may warrant antiviral therapy in some circumstances. 39, 40 HIV is an important yet overlooked cause of viral meningitis. The yield of testing for HIV was shown in one report from North Carolina where stored CSF samples from 57 patients who had presented with non-bacterial meningitis were retrospectively tested for HIV RNA. This was detected in three patients, two of whom had acute HIV infection as the likely cause for their presentation. None had been prospectively diagnosed. 41 Not all patients with aseptic meningitis have viral meningitis, and it is important to consider other causes if a viral aetiology is not confirmed by PCR. 42 Suspicion for a non-viral aetiology should be heightened in those with a subacute presentation, in immunosuppressed patients, in people from tuberculosis-endemic countries, in those with risk factors for sexually transmitted infection and in those with exposure to farm animals, faecally contaminated water or who have recently travelled to countries in Southeast Asia or the Pacific region.
Cryptococcal meningitis should be considered in patients with a subacute presentation. While this disease is commonly associated with acquired immunodeficiency syndrome (AIDS) or other forms of immunosuppression, it can also occur in seemingly immunocompetent people; amongst HIV negative patients with cryptococcal meningitis, 30% have no identifiable risk factors for this disease. 21 Typical CSF parameters are shown in Table 2 , although cryptococcal meningitis can be present despite normal CSF parameters in patients with HIV infection. 43 A high opening pressure is characteristic of this condition, and the diagnosis can be confirmed through CSF analysis for cryptococcal antigen, India ink staining and fungal cultures, which are positive in 97%, 51% and 89% of HIVnegative cases respectively. 21 TBM can present as either an acute or subacute illness and should be considered in people who have lived in a low-or middle-income country. If TBM is suspected, a large volume of CSF (10-20 mL) should be sent to the lab for acid-fast stain, PCR (such as with the GeneXpert MTB/RIF system) and mycobacterial cultures (which require incubation for up to 6 weeks). 27 The yield of these investigations is improved by testing large volumes of CSF, but all tests suffer from imperfect sensitivity, which is approximately 30% for acid-fast stain and approximately 60% for PCR or culture. 44, 45 Listeria meningitis may present with symptoms and CSF parameters that mimic viral meningitis. Intracerebral abscess may also present in a similar manner, with or without focal neurological signs. 46 Leptospirosis can cause acute meningitis; this diagnosis should be considered in those who work with animals or who have had exposure to faecally contaminated water. 47 Meningitis can be a manifestation of secondary syphilis. 1 In a patient with CSF eosinophilia of ≥10% or peripheral blood eosinophilia, and with recent travel to Southeast Asia or the Pacific region, eosinophilic meningitis (most commonly caused by Angiostrongylus cantonensis) should be considered, particularly if the patient gives a history of consumption of fresh vegetables or raw snails. Eosinophils can be misidentified as neutrophils if CSF analysis is automated, and thus the laboratory should be alerted if this diagnosis is suspected. 48 
Management
Immediate priorities, before and on arrival to hospital
In bacterial meningitis, prompt treatment is life-saving. For patients who present to primary care with suspected meningococcal disease, pre-hospital treatment with parenteral benzylpenicillin or ceftriaxone has been advocated. 19, 31 Intuitively, the benefits of early antibiotic administration seem clear. However, evidence that this practice improves outcomes is lacking; observational studies have reported that pretreated patients have worse outcomes, although this may be because those who were pretreated had more severe disease than those who were not. 49 An alternative hypothesis for this finding is that rapid bacteriolysis following antibiotic administration may precipitate shock due to the release of meningococcal endotoxins; this could be deleterious if it occurs in the community, rather than in the hospital where there is greater access to fluid resuscitation and inotropic support. This theory is also unproven. 49 Given this lack of evidence, the role of pre-hospital antibiotics remains unclear; they should be given to patients who present to rural or remote practices and face a prolonged transport time to a secondary care facility. 31 On arrival at hospital, the patient should be placed in droplet precautions to prevent potential nosocomial transmission of meningococcal infection and resuscitated as required. 8 Blood and, ideally, CSF cultures should be quickly obtained, following which dexamethasone and antibiotics should be given, aiming for administration within 1 h of admission. 4 The importance of timely therapy has been demonstrated in multiple studies, with one study showing an increase in mortality of 13% 4 and another showing an increase in mortality and disability of 30% 50 for every hour that treatment is delayed. In most cases, CSF should be obtained prior to the commencement of antimicrobials, although in certain situations, this introduces an unacceptable delay to treatment; these situations include the need to obtain a CT prior to LP, a clinical contraindication to LP, multiple failed attempts at this procedure or in patients with septic shock. 19 In these cases, dexamethasone and antibiotics should be given once blood cultures have been drawn, and CSF should be obtained at the earliest possible opportunity.
Early consultation with an infectious diseases physician may improve patient outcomes. In one study, patients with bacterial meningitis who were managed by infectious diseases physicians were significantly more likely to commence antibiotics within 1 h of presentation and to receive dexamethasone, and were less likely to experience treatment delays while awaiting neuroimaging. 5 
Empirical therapy
Most guidelines recommend dexamethasone plus ceftriaxone in the initial empirical treatment of communityacquired bacterial meningitis in adults. While the North American guideline 13 recommends the addition of vancomycin for all patients, guidelines from Australia, 31 the UK 19 and Europe 14 recommend the addition of vancomycin only for patients who are more likely to have pneumococcal meningitis or who have personal or epidemiological risk factors for being infected with a S. pneumoniae strain with reduced susceptibility to ceftriaxone. In Australia, the inclusion of vancomycin in the initial empirical regimen is recommended for patients with known or suspected otitis media or sinusitis, for those who have been treated with beta-lactam antibiotics recently and for those with Gram-positive cocci in the CSF or with a positive pneumococcal BAT. 31 An anti-Listeria agent should also be added for patients with risk factors for Listeria meningitis (age ≥ 50, long-term use of glucocorticoids or other immunosuppressive drugs, diabetes, alcoholism, cirrhosis, end-stage renal failure, malignancy, HIV infection and organ transplantation). 10 Benzylpenicillin and trimethoprim/sulfamethoxazole are active against L. monocytogenes, but ceftriaxone and vancomycin are not. An approach to initial investigation and management is summarised in Figure 1 , and an approach to empirical therapy is summarised in Table 3 .
Dexamethasone
Dexamethasone reduces cerebral inflammation, oedema and ICP in experimental models of bacterial meningitis. 51 In a meta-analysis of clinical trials, early treatment with dexamethasone reduced mortality rates in patients with pneumococcal meningitis from 36% to 30%, as well as significantly reducing hearing loss and other neurological sequelae. 2 These beneficial effects were not seen in a subgroup analysis of patients with meningococcal meningitis, although dexamethasone treatment is unlikely to be harmful in this group if given.
14 Guidelines recommend the empirical use of 10 mg dexamethasone intravenously (IV) every 6 h in patients with bacterial
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Internal Medicine Journal 48 (2018) 1294-1307meningitis, 13, 14, 19, 31 although it would be reasonable to omit this if the clinical presentation strongly suggests meningococcal meningitis. Other corticosteroids should not be used due to their inferior CNS penetration. 13 Dexamethasone should be started before or at the same time as the first antibiotic dose in order to attenuate cerebral inflammation caused by antibiotic-mediated bacteriolysis. 2 It is unclear if dexamethasone has any benefit when started after the first antibiotic dose, although some experts recommend that it can be started up to 4 h after this. 14 There have been theoretical concerns that dexamethasone may decrease antibiotic penetration into the CNS by reducing meningeal inflammation; however, one study demonstrated adequate CSF vancomycin concentrations despite treatment with dexamethasone. 52 For unclear reasons, the beneficial effects of dexamethasone
Draw bloods including blood cultures
Is there an indication for CT head prior to LP? (Table 1) 10mg dexamethasone IV q6h and antibiotics (Table 3) Obtain CT head
Yes
Is there a clinical contraindication to LP? † 10mg dexamethasone IV q6h and antibiotics (Table 3) Perform LP as soon as safely possible
Perform LP 10mg dexamethasone IV q6h and antibiotics (Table 3) Tailor to directed therapy once pathogen identified
No No
Urgently address airway or circulatory compromise
Use droplet precautions Figure 1 Initial investigation and management of adults with suspected bacterial meningitis. †Anti-coagulation, anti-platelet therapy other than aspirin, dual anti-platelet therapy, clinical evidence of disseminated intravascular coagulation, local infection or loss of skin integrity at puncture site, raised intracranial pressure on computed tomography (CT) head if performed. IV, intravenous; LP, lumbar puncture.
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Internal Medicine Journal 48 (2018) 1294-1307 © 2018 Royal Australasian College of Physicians seem confined to high-income countries, which is unfortunate given that bacterial meningitis is many times more prevalent in the developing world.
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If pneumococcal meningitis is diagnosed, treatment with dexamethasone should be continued for 4 days. Dexamethasone can be stopped if meningococcal meningitis is diagnosed.
14 Dexamethasone should also be stopped if Listeria meningitis is diagnosed as there is evidence that patients who receive this treatment have a higher mortality rate than those who do not. 53 
Antibiotics
Because almost all strains of N. meningitidis and many strains of S. pneumoniae are sensitive to ceftriaxone, most guidelines recommend 2 g ceftriaxone IV every 12 h. 13, 14, 19, 31 It is important to note that ceftriaxone provides no cover for L. monocytogenes. 13 In those with IgEmediated allergies to penicillins (including anaphylaxis), ceftriaxone is likely to be safe due to negligible rates of cross-reactivity between penicillins and third-generation cephalosporins. 54 However, in those with severe T cellmediated reactions to penicillins, such as toxic epidermal necrolysis or Stevens-Johnson syndrome, the safety of ceftriaxone is not well established. For these patients, moxifloxacin can be used as an alternative empirical therapy, or ciprofloxacin plus vancomycin if moxifloxacin is not available.
S. pneumoniae isolates were uniformly susceptible to penicillin and ceftriaxone prior to the 1970s. However, since then, the proportion of strains with a modestly increased minimum inhibitory concentration (MIC) to these antibiotics has steadily risen. Fortunately, this has not had major effects on the treatment of pneumococcal infections outside of the CNS as concentrations exceeding these modestly elevated MIC are readily achieved in serum and tissues by high-dose IV administration. In contrast, the concentration of either penicillin or ceftriaxone that is achieved in the CSF is many times lower than that in the serum and may be too low to be active against the infecting strain of S. pneumoniae. 55 MIC breakpoints of penicillin are defined differently for meningitis and non-meningitis infections caused by S. pneumoniae (Table 4) . Figure 2A shows the distribution of penicillin MIC for 37 742 isolates of S. pneumoniae, 57 and 2B the concentrations of penicillin in serum and in CSF during 4 h after the IV administration of 1.2 g benzylpenicillin. 58 In all patients at 1 h after treatment, and in most patients at 2 h after treatment, the concentration of penicillin in serum exceeded the MIC of all pneumococcal isolates. In contrast, no patient had a CSF penicillin concentration that exceeded the MIC of all pneumococcal isolates at any point during the 4 h after administration. However, in all patients throughout the 4-h period, the concentrations of penicillin in CSF were >0.06 mg/L. Studies of animals with pneumococcal meningitis treated with beta-lactam antibiotics, such as penicillin or ceftriaxone, show that maximal bacterial killing is achieved when the CSF concentrations of the beta-lactam antibiotic exceed the minimum bactericidal concentration (MBC) of the antibiotic for >90% of the treatment interval. 62 Because the MIC MIC, minimum inhibitory concentration.
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Internal Medicine Journal 48 (2018) 1294-1307 © 2018 Royal Australasian College of Physicians closely approximates the MBC for most beta-lactam antibiotics, the presence of antibiotic concentrations greater than the MIC throughout each treatment interval is likely to provide maximal bacterial killing. Treatment with benzylpenicillin (2.4 g IV every 4 h) is therefore very likely to be effective for patients with pneumococcal meningitis caused by strains with MIC ≤ 0.06 mg/L but less likely to be effective for patients with meningitis caused by strains with penicillin MIC > 0.06 mg/L. Figure 2C shows the distribution of ceftriaxone MIC for 3238 isolates of S. pneumoniae, 57 and Figure 2D shows the concentrations of ceftriaxone in serum 59 and in CSF 60,61 during 24 h after the IV administration of 2 g ceftriaxone. Throughout the 24-h period, the concentrations of ceftriaxone in serum were consistently higher than the MIC of all strains of S. pneumoniae, and the concentrations of ceftriaxone in CSF were consistently ≥1 mg/L. Treatment with ceftriaxone (2 g IV every 12 h) is therefore very likely to be effective for the majority of patients with pneumococcal meningitis but may be ineffective in patients with meningitis caused by S. pneumoniae strains with ceftriaxone MIC >2 mg/L.
Because CSF concentrations of ceftriaxone may not be sufficient to treat S. pneumoniae strains with reduced susceptibility to ceftriaxone, the supplementation of initial therapy with vancomycin should be considered. In Australia, the addition of vancomycin is recommended for patients who are most likely to have pneumococcal meningitis, such as those with known or suspected otitis media or sinusitis and those who have Gram-positive cocci seen in the CSF analysis or a positive pneumococcal BAT. 31 Vancomycin should also be added for patients with risk factors for infection with a S. pneumoniae strain with reduced susceptibility to ceftriaxone, such as those treated with beta-lactam antibiotics in the last 3 months; recent hospitalisation and residence in a long-term care facility have also been identified as risk factors for a resistant strain. 63 If pneumococcal meningitis is confirmed, vancomycin should be continued until the ceftriaxone MIC is available. 64 In Australia, in 2012, 10% of S. pneumoniae isolates from sterile sites demonstrated decreased susceptibility to penicillin (MIC > 0.06 mg/L), but only 2% demonstrated decreased susceptibility to ceftriaxone (MIC > 0.5 mg/L). 65 At Auckland City Hospital in New Zealand during 2017, 35% of S. pneumoniae isolates from blood or CSF demonstrated decreased susceptibility to penicillin, while 11% demonstrated decreased susceptibility to ceftriaxone, suggesting that the addition of vancomycin should be routine when empirically treating patients with meningitis in Auckland. 66 Resistance to vancomycin has not yet been reported for S. pneumoniae. 
Other considerations
Many patients with bacterial meningitis are critically unwell and will require support in the intensive care unit. This may include airway support with mechanical ventilation, circulatory support with inotropes, medical or surgical reduction of raised ICP and medical management of coagulopathy, hyponatraemia and seizures. Later in the course of meningococcal disease, those with purpura fulminans may require debridement or amputation of necrotic tissues and reconstruction with skin grafts or flaps. 67 For adults with pneumococcal meningitis, predisposing conditions, such as otitis media, sinusitis or mastoiditis, should be sought and managed in conjunction with otorhinolaryngology if required. 9 
Directed therapy
Once a presumptive microbiological diagnosis has been provided by Gram stain or confirmed by culture or PCR, further therapy can be directed at the identified pathogen. 13 
Streptococcus pneumoniae
For pneumococcal meningitis, a 10-14-day course of IV therapy should be completed, with dexamethasone given during the first 4 days. 13 In patients infected with ceftriaxone-susceptible strains, vancomycin can be discontinued and treatment continued with 2 g ceftriaxone IV every 12 h. If the isolate is penicillin-susceptible, clinicians may consider changing to 2.4 g benzylpenicillin IV every 4 h to avoid continuing with an unnecessarily broadspectrum agent. 56 If the isolate is ceftriaxone-intermediate or -resistant, options include continuing ceftriaxone and vancomycin if the patient has responded well to initial therapy (with consideration of the addition of rifampicin) or changing to 400 mg moxifloxacin IV every 24 h. 31, 68 Survivors have a 5% risk of recurrence of pneumococcal meningitis, and thus pneumococcal vaccination is recommended; this is particularly important for those with a predisposing immunodeficiency or CSF leak. 14 
Neisseria meningitidis
A dose of 1.8 g benzylpenicillin IV every 4 h should be used for the treatment of meningococcal meningitis in Australia and New Zealand. 31 Ceftriaxone can be used for patients with immediate penicillin hypersensitivity 54 and moxifloxacin or ciprofloxacin used for patients with severe T cell-mediated reactions to penicillins. 13, 31 While strains with intermediate susceptibility to penicillin are increasingly detected, high doses of penicillin are clinically effective. 69 Although frank resistance to penicillin remains rare, vigilance is required given the emergence of a penicillin-resistant clade of N. meningitidis serogroup W in 2016 and the identification of a penicillin-resistant serogroup B isolate in 2010, both from Western Australia. 69, 70 While most guidelines recommend between 5 and 7 days of antibiotic therapy for meningococcal meningitis, 13, 31, 64 experience with 88 patients during a very large meningococcal epidemic in New Zealand found that 3 days of benzylpenicillin was effective treatment, strongly suggesting that longer courses are unnecessary. 71 Dexamethasone can be stopped in patients with confirmed meningococcal meningitis. 14 Patients with meningococcal disease should be placed in droplet precautions until 24 h of antibiotic therapy has been given. 8 In cases of suspected or confirmed meningococcal disease, public health authorities should be notified and clearance antibiotics administered to close contacts. Options for non-pregnant persons include ciprofloxacin (a single 500 mg oral dose) or rifampicin (600 mg orally twice/day for 2 days); rifampicin should be avoided in women taking the oral contraceptive pill or in patients for whom there are other important drug interactions. Ceftriaxone (a single intramuscular dose of 250 mg) is the preferred option for pregnant women. Penicillin does not adequately eradicate nasopharyngeal carriage of meningococci; thus, clearance antibiotics are also required for the index case unless at least one dose of ceftriaxone has been given during treatment. Clearance antibiotics should be initiated as soon as possible, ideally on the day of diagnosis, but should still be given up to 14 days following exposure. Vaccination for close contacts is also recommended if the infecting organism is in a vaccine-preventable serogroup. However, serotyping usually requires referral of the specimen to a reference laboratory, and results may not be available within the appropriate timeframe to implement vaccination. 8, 72 Listeria monocytogenes A dose of 2.4 g benzylpenicillin IV every 4 h (or 2 g amoxicillin IV every 4 h) is the treatment of choice for meningitis caused by L. monocytogenes. Trimethoprim/sulfamethoxazole can be used for patients with penicillin allergy. 13 The addition of gentamicin appears to reduce mortality, although this has not been proven in randomised trials. 53, 64 Optimal treatment duration is unknown, but IV antibiotics are generally continued for at least 21 days. 13 Dexamethasone should be discontinued immediately if L. monocytogenes has been identified, because of the worse outcome in patients who receive dexamethasone. 53 
Viral meningitis
Dexamethasone and antibiotics can be discontinued if CSF parameters are consistent with viral meningitis, provided the clinical suspicion for bacterial meningitis is low. Enteroviral meningitis is self-limiting and requires only supportive care. HSV meningitis is also self-limiting in immunocompetent patients; symptomatic treatment alone is reasonable, although 7-10 days of antiviral treatment (with acyclovir, valacyclovir or famciclovir) has been shown to improve neurological outcomes in immunocompromised hosts. 39 It is vital to recognise that HSV encephalitis (usually caused by HSV-1) is a distinct entity from HSV meningitis (usually caused by HSV-2); in HSV encephalitis, treatment with IV acyclovir is critical in reducing mortality and disability. 40 The optimal treatment of VZV meningitis is unknown, although most clinicians would give antivirals unless the patient was already improving without therapy. 40 Meningitis caused by acute HIV infection requires ongoing follow up and management from an experienced specialist.
Deteriorating patients
Neuroimaging is indicated in patients who fail to improve or in whom neurological abnormalities or seizures develop, to evaluate for hydrocephalus, venous sinus thrombosis, subdural empyema or intracerebral abscess. These complications occur most commonly in patients with pneumococcal meningitis. 67 Repeat LP should be considered in those who fail to improve after 48 h of treatment and who have unremarkable neuroimaging; this is particularly important for patients with meningitis caused by a strain of S. pneumoniae with reduced susceptibility to ceftriaxone. 13 
Primary prevention
Childhood vaccination against Haemophilus influenzae serotype b has led to the near-complete elimination of meningitis caused by this pathogen in countries with adequate vaccination coverage. 72 Pneumococcal vaccination is incorporated into the immunisation schedules of both Australia and New Zealand; vaccination has reduced the rates of pneumococcal meningitis in children and adults, albeit with a rise in the proportion of cases caused by serotypes not included in vaccines. 72 No effective vaccines have been developed against L. monocytogenes.
In Australia, most cases of meningococcal disease are caused by serogroups W, B and Y, which were responsible for 43%, 36% and 16% of cases in 2016 respectively. 73 Serogroup C disease has become very rare since the conjugate meningococcal C vaccine was introduced to the Australian immunisation schedule in 2003, with the exception of an outbreak of serogroup C disease in 2017 among men who have sex with men in Melbourne. 74, 75 In 2018, the serogroup C vaccine was replaced in the Australian immunisation schedule by a quadrivalent conjugate vaccine against serogroups A, C, W and Y, which is administered at 12 months of age. 74 In New Zealand, meningococcal serogroups B and C are of the most importance, but no meningococcal vaccines are included in the New Zealand immunisation schedule. 72 Vaccination against serogroups A, C, W and Y is recommended for people at high risk of meningococcal disease, including patients with terminal complement deficiencies or asplenia, those with HIV infection, military recruits and some travellers, such as those whose destination is the 'meningitis belt' in subSaharan Africa. For pilgrims to the Hajj in Saudi Arabia, quadrivalent meningococcal vaccination is a requirement of entry. 72 Producing effective vaccines against meningococcal serogroup B has proven difficult due to its poorly immunogenic capsule. In New Zealand, between 2004 and 2008, the MeNZB vaccine was offered to children and adolescents and had a modest effect on the nationwide meningococcal epidemic; however, this vaccine was targeted against the epidemic strain alone and produced only a relatively weak and short-lived immune response. 72 Advances have occurred in serogroup B vaccine development, and a vaccine (Bexsero, GlaxoSmithKline) that is immunogenic against an estimated 76% of group B meningococcal strains is now available in Australia for private purchase. The duration of protection remains unknown.
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Conclusion
The likelihood of confirming the responsible pathogen in cases of community-acquired bacterial meningitis has been improved by newer techniques, such as multiplex PCR. However, a thorough understanding of the interpretation of basic CSF parameters, as well as the caveats of relying on CSF parameters alone to exclude bacterial meningitis, is required to accurately diagnose this often terrifying condition. Clinicians should collect blood cultures and CSF and initiate treatment within 1 h of making a presumptive clinical diagnosis of bacterial meningitis. They should be aware of the worse outcomes that occur when neuroimaging unnecessarily delays LP and the initiation of treatment. Prompt therapy with dexamethasone plus ceftriaxone, with the addition of vancomycin and/or benzylpenicillin when indicated, improves the chance of a positive outcome for patients affected by this devastating and disabling disease.
